<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38338">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01684722</url>
  </required_header>
  <id_info>
    <org_study_id>39113-EA</org_study_id>
    <secondary_id>R01DK088762</secondary_id>
    <nct_id>NCT01684722</nct_id>
  </id_info>
  <brief_title>Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease</brief_title>
  <acronym>VITAL-DKD</acronym>
  <official_title>Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in
      20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin
      D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing
      cancer, heart disease, and stroke in people who do not have a prior history of these
      illnesses. This ancillary study is being conducted among participants in VITAL with a
      history of diabetes and will examine whether vitamin D or fish oil prevents the development
      and progression of diabetic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) will test whether vitamin
      D3, omega-3 fatty acids, or both prevent the development and progression of diabetic kidney
      disease (DKD). Persons with diabetes are at high risk of kidney disease. In 2005-2008, the
      prevalence of DKD among people with type 2 diabetes in the United States was 34.5%.
      Moreover, from 1988-1994 to 2005-2008, the prevalence of DKD in the United States grew 34%
      to 6.9 million people. DKD is both the leading cause of end stage renal disease in the
      developed world and a potent amplifier of cardiovascular disease risk.

      Vitamin D and omega-3 fatty acids are promising interventions for DKD prevention and
      treatment, based on results of animal-experimental models and early human studies.  Because
      these interventions are relatively safe, inexpensive, and widely available, they may offer
      opportunity to substantially reduce the burden of DKD in large populations.  This VITAL
      ancillary study will test whether vitamin D3 and/or omega-3 fatty acids prevent progression
      of albuminuria and loss of glomerular filtration rate, two complementary manifestations of
      DKD, over 3 years of treatment.

      In VITAL, 20,000 participants will be randomly assigned in a 2x2 factorial design to vitamin
      D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid 465 mg plus
      docosahexaenoic acid 375 mg daily versus placebo, and followed for a mean of 5 years to
      assess effects on cardiovascular disease and cancer events. This ancillary study will
      identify and recruit a sub-cohort of VITAL participants with diabetes at baseline and
      ascertain effects of study interventions on albuminuria and glomerular filtration rate in
      this group. First morning voids will be collected at baseline and year 3 for measurement of
      urine albumin-creatinine ratio.  Blood samples will be collected simultaneously for
      measurement of estimated glomerular filtration rate (using serum creatinine and cystatin C)
      and other relevant biomarkers. This VITAL ancillary study is designed to determine whether
      vitamin D3 and/or omega-3 fatty acids have causal and clinically relevant effects on the
      development and progression of DKD.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in urine albumin excretion</measure>
    <time_frame>baseline and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate</measure>
    <time_frame>baseline and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control</measure>
    <time_frame>baseline and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein</measure>
    <time_frame>baseline and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>baseline and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1320</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D and omega-3 fatty acids (fish oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D and fish oil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D placebo and omega-3 fatty acids (fish oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin D placebo and fish oil placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids (fish oil)</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D placebo</intervention_name>
    <description>Vitamin D3 placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participants in VITAL (NCT 01169259) with a self-reported physician
        diagnosis of diabetes are eligible to participate in this ancillary study.

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Diabetes only during pregnancy

          -  Known cause of kidney disease other than diabetes

          -  History of kidney transplantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian H de Boer, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org/</url>
    <description>Vitamin D and Omega-3 Trial study website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>fish oil</keyword>
  <keyword>diabetes</keyword>
  <keyword>kidney disease</keyword>
  <keyword>albuminuria</keyword>
  <keyword>urine albumin excretion</keyword>
  <keyword>glomerular filtration rate</keyword>
  <keyword>diabetic kidney disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
